Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes

American Journal of Hematology

Volumn 82, Issue 12, 2007, Pages 1080-1087

  Mohamed, Anwar N ^a,b   Bentley, Gail ^a   Bonnett, Michelle L ^a   Zonder, Jeff ^a   Al Katib, Ayad ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cytogenetics Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CONTROLLED STUDY; FEMALE; HUMAN; KARYOTYPE; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; DIPLOIDY; FEMALE; HUMANS; KARYOTYPING; MALE; METAPHASE; MULTIPLE MYELOMA; PARAPROTEINEMIAS; SEQUENCE DELETION;

EID: 36749014487     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20998     Document Type: Article

References (39)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;336:1657-1664.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. pp 42-156.
3. Grogan TM, Spier CM. The B-cell immunoproliferative disorders; including multiple myeloma and amyloidosis. In: Knowles DM, editor. Neoplastic Hematopathology, 2nd ed. Lippincott Williams and Wilkins: Philadelphia; 2001.
4. Reece DE. An update of the management of multiple myeloma: The changing landscape. Am Soc Hematol Educ Program 2005;353-359.
5. Durie BG. Staging and kinetics of multiple myeloma. Semin Oncol 1986;13:300-309.
6. Scudla V, Zemanova M, Minarik J, Bacovsky J, et al. International prognostic index (IPI) - A critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy. Neoplasm 2006;53:277-284.
7. Dewald Gw, Kyle RA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985;66:380-390.
8. Lai JI, Zandecki M, Mary JY, et al. Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 1995;85:2490-2497.
9. Calasanz MJ, Cigudosa JC, Odero MD, et al. Cytogenetics analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations. Genes Chromosomes Cancer 1997;18:84-93.
10. Sawyer JR, Waldrom JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995;82:41-49.
11. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: A workshop report. Cancer Res 2004;64:1546-1558.
12. Gutierrez NC, Garcia JL, Hernandez JM, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004;104:2661-2666.
13. Dewald GW, Therneau T, Larson D, et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005;106:3553-3558.
14. Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 2005;44:194-203.
15. Tricot G, Barlogie B, Jagannath S, et al. Poor prognosis in multiple myeloma is associated only with partial deletion or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-4256.
16. Zojer N, Konigsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000;95:1925-1930.
17. Harrison CJ, Mazzullo H, Cheung KI, et al. Cytogenetics of multiple myeloma: Interpretation of fluorescence in situ hybridization results. Br J Haematol 2003;120:944-952.
18. Lloveras E, Granada I, Zamora L, et al. Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia. Cancer Genet Cytogenet 2004;148:71-76.
19. Seong C, Delasalle K, Hayes K, et al. Prognostic value of cytogenetics in multiple myeloma. Br J Haematol 1998;101:189-194.
20. Smadja NV, Fruchart C, Isnard F, et al. Chromosome analysis in multiple myeloma: Cytogenetic evidence of two different diseases. Leukemia 1998;12:960-969.
21. Fonseca R, Debes-Marun C, Picken E, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003;102:1562-2567.
22. Smadja NV, Leroux D, Soulier J, et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 2003;38:234-239.
23. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002;99:2185-2191.
24. Wuilleme S, Robillard N, Lode L, et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 2005;19:275-278.
25. Harris MB, Shster JJ, Carroll A. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: A pediatric oncology group study. Blood 1992;79:3316-3324.
26. Heerma NA, Sather HN, Sensel MG, et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (>50 chromosomes). J Clin Oncol 2000;18:1876-1887.
27. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001;98:2229-2238.
28. Kaufmann H, Kromer E, Nosslinger T, et al. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion 13q by interphase FISH only are prognostically relevent in multiple myeloma. Eur J Haematol 2003;71:179-183.
29. Fassas AB, Spencer T, Sawyer J, et al. Both hypodiploidy and deletion 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002;118:1041-1047.
30. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001;20:5611-5622.
31. Avet-Loiseau H, Li JY, Facon T, et al. High incidence of Ig heavy chain gene in multiple myeloma, as shown by fluorescence in situ hybridization. Genes Chromosomes Cancer 1999;24:9-15.
32. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Am Soc Hematol 2005;346-352.
33. Yamamoto K, Hamaguchi H, Nagata K, Taniwaki M. A variant Burkitt-type translocation (8;22)(q24;q11) in multiple myeloma. Report of a new case and review of the literature. Cancer Genet Cytogenet 1998;104:98-103.
34. Stewart K, Fonseca R. Prognostic and theraputic significance of myeloma genetics and gene expression profiling. J Clin Oncol 2005;23:6339-6344.
35. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. New Eng J Med 2000;343:1910-1916.
36. Mohamed AN, Wolman SR. Chromosome analysis in cell culture. In: Studzinski G, editor. Cell Growth and Apoptosis: A Practical Approach, 2nd ed. Oxford: Oxford University Press; 1995. pp 79-96.
37. ISCN. An International System for Human Cytogenetic Nomenclature. Shaffer LG, Tommerup N, editors. Basel: S. Karger; 2005.
38. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003;101:4569-4575.
39. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;26:6333-6338.